Tesamorelin: Discovery and Regulatory History

Introduction

Tesamorelin's development history traces a path from fundamental neuroendocrine science through applied pharmaceutical chemistry to regulatory approval. The compound represents the clinical endpoint of a research trajectory initiated in the early 1980s with the isolation and structural characterization of endogenous human growth hormone-releasing hormone (GHRH). An understanding of that trajectory — encompassing the discovery of native GHRH, the recognition of its therapeutic constraints as a drug candidate, the engineering of a stabilized analog, and the clinical trials that preceded regulatory approval — provides context for situating tesamorelin within the broader pharmacology of the GH axis.

Discovery Period: Isolation of Endogenous GHRH (1982)

The identity of the hypothalamic factor responsible for stimulating pituitary growth hormone (GH) secretion remained elusive for two decades after the existence of such a factor was postulated in the 1950s. The challenge was substantial: the peptide was produced in small quantities in hypothalamic neurons and was rapidly degraded in the peripheral circulation, making isolation from hypothalamic tissue exceedingly difficult.

The breakthrough came in 1982 from an unexpected source. Guillemin, Brazeau, Böhlen, Esch, Ling, and Wehrenberg reported the isolation and structural characterization of a 44-amino acid peptide from the pancreatic tumor of an acromegalic patient — a patient whose pituitary had been chronically overstimulated by tumor-derived ectopic GHRH secretion. The isolated peptide was characterized as growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly, and its complete amino acid sequence was published in Science [1].

Independently and concurrently, Rivier and colleagues isolated a homologous 40-residue peptide from a second acromegalic patient's pancreatic tumor and published the structure in Nature the same year. Human hypothalamic GHRH was subsequently confirmed to share the primary sequence of these tumor-derived peptides, validating the ectopic tumor tissue as an accessible source for characterizing what had previously been an intractable target [1].

These discoveries completed the characterization of the two principal hypothalamic regulators of GH secretion: GHRH (stimulatory) and somatostatin (inhibitory), the latter having been isolated by Guillemin's group a decade earlier and recognized by the Nobel Committee with the Nobel Prize in Physiology or Medicine in 1977.

Early Research: From Native GHRH to Synthetic Analogs

Following the structural characterization of human GHRH(1-44)-NH₂, the 1980s saw rapid development of synthetic GHRH preparations for research use. Native GHRH was synthesized chemically and demonstrated in laboratory settings to stimulate GH release from cultured pituitary cells and in vivo in rodent models.

The pharmacokinetic limitations of native GHRH were recognized early. DPP-IV cleaves the first two N-terminal residues (Tyr-Ala) to produce GHRH(3-44), a fragment with substantially reduced GHRH receptor affinity. The biological half-life of native GHRH in human circulation is measured in minutes, creating a fundamental obstacle for sustained receptor engagement. Through the late 1980s and 1990s, multiple research groups investigated structural modifications that might confer DPP-IV resistance without sacrificing receptor affinity — work that established the medicinal chemistry principles Theratechnologies would apply in developing tesamorelin. A parallel line of GHRH analog development, documented in the CJC-1295 without DAC history, pursued different N-terminal stabilization strategies over the same period.

Theratechnologies' Development Program

Theratechnologies Inc., a Montreal-based biopharmaceutical company, initiated a GHRH analog development program with the goal of identifying a compound suitable for clinical development in an indication where GH-axis modulation had established pharmacological rationale.

The scientific rationale for HIV-associated lipodystrophy as a target indication was grounded in documented GH secretory abnormalities in HIV-infected patients on long-term antiretroviral therapy. Multiple research groups had characterized a pattern of blunted GH pulsatility and altered GH-IGF-1 axis activity in this population, alongside the visceral adiposity accumulation that is the hallmark of HIV-associated lipodystrophy.

Theratechnologies' key synthetic contribution was the conjugation of a trans-3-hexenoic acid moiety to the alpha-amine of the first amino acid residue (tyrosine) of human GHRH(1-44)-NH₂. This N-terminal modification sterically impedes DPP-IV cleavage while preserving the peptide's receptor-binding capacity. The resulting compound — designated TH9507 in development and subsequently assigned the international nonproprietary name tesamorelin — demonstrated a meaningfully extended pharmacokinetic profile relative to native GHRH in preclinical characterization.

Phase 1 and early phase 2 studies conducted in the late 1990s and early 2000s established the pharmacokinetic and pharmacodynamic profile of tesamorelin in human subjects, documenting GH pulsatility augmentation and IGF-1 elevation, and providing initial safety data that supported advancement to larger randomized trials.

Regulatory Milestones

The pivotal phase 3 regulatory program comprised two large randomized, double-blind, placebo-controlled trials in HIV-infected patients with lipodystrophy, referred to in regulatory documentation as LIPO-010 and LIPO-011. These trials collectively enrolled over 800 patients and provided the primary efficacy and safety evidence supporting the marketing authorization application.

Falutz and colleagues published initial findings from this program in the New England Journal of Medicine in December 2007, reporting statistically significant reductions in visceral adipose tissue in tesamorelin recipients compared to placebo over 26 weeks [2]. The full phase 3 dataset, including safety extension data, was subsequently published in the Journal of Acquired Immune Deficiency Syndromes in 2010 [3].

November 10, 2010: The FDA approved tesamorelin under the brand name Egrifta (NDA 022505) for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [4]. This approval represented the first regulatory authorization for any GHRH analog in the United States and the first approved pharmacological treatment specifically for HIV-associated lipodystrophy.

2011–2012 (European Medicines Agency review): The European Medicines Agency reviewed the tesamorelin marketing authorization application during this period. The EMA's Committee for Medicinal Products for Human Use issued a negative opinion, citing its assessment of the benefit-risk profile in the European regulatory context. The marketing authorization was consequently not granted in the European Union; Egrifta's geographic approval has remained principally in the United States and Canada. The divergence between US and EU regulatory outcomes for the same phase 3 dataset reflects the inherent differences in regulatory-agency risk-benefit frameworks, a pattern seen across multiple specialty pharmaceutical approvals in this era.

May 2019: Egrifta SV (Single Vial) received FDA approval via a supplemental application. The SV formulation delivers a more concentrated solution requiring a simplified one-step reconstitution process compared to the original two-vial preparation, addressing a practical burden identified in post-approval clinical experience.

March 2025: Egrifta WR (Weekly Reconstitution) received FDA approval of a supplemental biologics license application. The WR formulation allows weekly reconstitution rather than daily preparation required by earlier formulations, reflecting continued formulation development by Theratechnologies [4].

Expanding Research Program

Following the 2010 FDA approval, research activity on tesamorelin expanded to address questions not resolved by the pivotal trials. The Grinspoon laboratory at Massachusetts General Hospital published a mechanistic investigation of GH-axis pharmacodynamics in healthy men (2011) [5], characterizing GH pulsatility preservation during GHRH-R agonism and providing the pharmacodynamic framework for subsequent work.

Stanley and colleagues published a randomized controlled trial in JAMA in 2014 examining tesamorelin's effects on visceral and liver fat in HIV-infected adults [6], building on the pivotal trial findings and opening the line of hepatic investigation. A dedicated randomized trial in The Lancet HIV (2019) reported tesamorelin-associated reductions in hepatic fat fraction and fibrosis progression relative to placebo in HIV-infected individuals with NAFLD [7] — the first randomized evidence for a pharmacological agent targeting NAFLD outcomes in this population. A parallel safety study published in PLOS ONE (2017) examined tesamorelin's metabolic effects in adults with type 2 diabetes and reported no significant worsening of glycemic control at 12 weeks [8], expanding the evidence base beyond the HIV context.

The compound's research trajectory — from the 1982 GHRH isolation through three decades of medicinal chemistry, clinical trials, and post-approval investigation — positions tesamorelin as the most thoroughly characterized GHRH analog in the published literature. Detailed synthesis and purity verification standards for research-grade material are described in the tesamorelin sourcing and quality article; research-grade tesamorelin from SpartaLabs is available with third-party COA documentation.

References

1. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-7. PMID: 6812220. DOI: 10.1126/science.6812220

2. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. DOI: 10.1056/NEJMoa072375

3. Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. PMID: 20101189

4. U.S. Food and Drug Administration. Summary Review for Regulatory Action: Egrifta (tesamorelin for injection), NDA 022505. Silver Spring: FDA; 2010. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000SumR.pdf

5. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-8. PMID: 20943777. DOI: 10.1210/jc.2010-1587

6. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. PMID: 25038355. DOI: 10.1001/jama.2014.8334

7. Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PMID: 31611038. DOI: 10.1016/S2352-3018(19)30338-8

8. Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, et al. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLOS ONE. 2017;12(6):e0179538. PMID: 28632777. DOI: 10.1371/journal.pone.0179538